Angelman Syndrome Overview
Angelman syndrome (AS) is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene in the 15th chromosome derived from the mother. Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability.
“Angelman Syndrome Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Angelman Syndrome Market.
The Angelman Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Angelman Syndrome Pipeline Report:
Angelman Syndrome Pipeline Therapeutics Assessment
DelveInsight’s Angelman Syndrome Report covers around 15+ products under different phases of clinical development like
Emerging Angelman Syndrome Drugs Under Different Phases of Clinical Development Include:
Get a Free Sample PDF Report to know more about Angelman Syndrome Pipeline Assessment-
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight
Angelman Syndrome Pipeline Analysis:
The Angelman Syndrome pipeline report provides insights into
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Angelman Syndrome product details are provided in the report. Download the Angelman Syndrome pipeline report to learn more about the emerging Angelman Syndrome therapies
Angelman Syndrome Pipeline Market Drivers
Angelman Syndrome Pipeline Market Barriers
Scope of Angelman Syndrome Pipeline Drug Insight
Request for Sample PDF Report for Angelman Syndrome Pipeline Assessment and clinical trials
Table of Contents
1
Angelman Syndrome Report Introduction
2
Angelman Syndrome Executive Summary
3
4
Angelman Syndrome- Analytical Perspective In-depth Commercial Assessment
5
Angelman Syndrome Pipeline Therapeutics
6
Angelman Syndrome Late Stage Products (Phase II/III)
7
Angelman Syndrome Mid Stage Products (Phase II)
8
Angelman Syndrome Early Stage Products (Phase I)
9
Angelman Syndrome Preclinical Stage Products
10
Angelman Syndrome Therapeutics Assessment
11
Angelman Syndrome Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
Angelman Syndrome Key Companies
14
Angelman Syndrome Key Products
15
Angelman Syndrome Unmet Needs
16
Angelman Syndrome Market Drivers and Barriers
17
Angelman Syndrome Future Perspectives and Conclusion
18
Angelman Syndrome Analyst Views
19
Appendix
20
About DelveInsight
Download Sample PDF Report to know more about Angelman Syndrome drugs and therapies
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting